Chabiotech Co.,Ltd. (KOSDAQ:085660)

Market Cap	577.65B
Revenue (ttm)	1.05T
Net Income (ttm)	-8.05B
Shares Out	55.97M
EPS (ttm)	-143.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	340,338
Average Volume	412,942
Open	10,550
Previous Close	10,510
Day's Range	10,270 - 10,680
52-Week Range	9,260 - 18,500
Beta	0.41
RSI	44.72
Earnings Date	May 14, 2025

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 292
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.